Indications for SKYRIZI:
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Administer by SC inj into abdomen, thighs (or may be given by healthcare provider only in upper, outer arm). ≥18yrs: 150mg (two 75mg injections) by SC inj at Weeks 0 and 4, then every 12 weeks thereafter.
<18yrs: not established.
Use under physician supervision and guidance. May increase risk of infections. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue Skyrizi until resolves. Evaluate for tuberculosis (TB) infection prior to initiating. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Monitor for signs/symptoms of active TB during and after therapy. Patients with active TB infection: do not initiate. Consider completion of all age appropriate immunizations according to current guidelines before starting therapy. Pregnancy. Nursing mothers.
Avoid use of live vaccines.
Upper respiratory infections, headache, fatigue, inj site reactions, tinea infections.
Generic Drug Availability:
Single-dose prefilled syringes—2 (w. supplies)